Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
18.68
-0.44 (-2.30%)
At close: Jan 8, 2026, 4:00 PM EST
18.93
+0.25 (1.34%)
After-hours: Jan 8, 2026, 6:25 PM EST
Neurogene Employees
Neurogene had 107 employees as of December 31, 2024. The number of employees increased by 16 or 17.58% compared to the previous year.
Employees
107
Change (1Y)
16
Growth (1Y)
17.58%
Revenue / Employee
n/a
Profits / Employee
-$795,607
Market Cap
289.35M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 107 | 16 | 17.58% |
| Dec 31, 2023 | 91 | 9 | 10.98% |
| Dec 31, 2022 | 82 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NGNE News
- 3 days ago - Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 5 weeks ago - Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Neurogene: From Speculation To Execution With NGN-401 - Seeking Alpha
- 2 months ago - Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates - Business Wire
- 2 months ago - Neurogene Inc. (NGNE) Presents at Stifel 2025 Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome - Business Wire
- 2 months ago - Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome - Business Wire
- 2 months ago - Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire